Personalized Plastic Surgery & Aesthetic Care in Seocho-gu, Seoul
Medical Guide
Rejuran Healer vs JUVELOOK vs Exosome Therapy Compared
Is there a best Korean skin booster? Compare Rejuran Healer, JUVELOOK, and exosome therapy by mechanism, evidence quality, and US regulatory standing.
Schedule a ConsultationRejuran Healer vs JUVELOOK vs Exosome Therapy: Three Mechanisms, Three Different Jobs
Medically reviewed by Dr. In-Ho Khang, MD, Yonsei University College of Medicine; Chief Academic Director of Plastic Surgery, Korean Society of Aesthetic Surgery & Laser (KSASL)
If you are weighing Rejuran Healer vs JUVELOOK vs exosome therapy, the productive question is not which is strongest. All three appear on the same treatment menus and get discussed as upgrades of one another, but they act through three genuinely different biological mechanisms, and each answers a different complaint. YONSEI LEEDS CLINIC in Seoul lists all three among its skin booster options and states that the formulation is selected after a physician skin assessment. This article compares them by mechanism, by the quality of the evidence behind each, and by the regulatory question that matters most for U.S. readers.
Why the Category Label Tells You Almost Nothing
A skin booster is an injectable placed into the skin to influence skin quality rather than to change contour the way a filler does. That is too broad to be a decision tool: inside the one category sit a nucleic acid from fish, a slowly degrading synthetic polymer, and biological nanoparticles from cultured cells.
Mechanism One: Polynucleotides and PDRN, the Rejuran-Type Category
Rejuran Healer belongs to a family of injectables built from fragmented DNA, most often sourced from the sperm cells of salmon or trout. Two abbreviations circulate almost interchangeably: PDRN for polydeoxyribonucleotide, and PN for polynucleotide. A 2025 review in Biomolecules proposed a molecular weight cutoff to separate them, and makes a more consequential point along the way: manufacturers generally do not disclose chain size, and processing can degrade the molecules below their stated specification. Two products listing the same concentration may behave differently.
Two mechanisms are proposed. The first is receptor-mediated: as enzymes break the fragments down, the resulting nucleosides are thought to act on the adenosine A2A receptor, a pathway associated with modulating inflammation and with cell activity in repair. The second is physical: higher-molecular-weight polynucleotide forms a viscous, water-binding gel that behaves as a scaffold loosely mimicking the skin's own extracellular matrix. A 2024 overview in Archives of Plastic Surgery describes both. Notice what is absent: bulk. This category is not designed to lift or fill.
What the evidence shows, and where it stops
A 2024 systematic review in the Journal of Cosmetic Dermatology screened 1,391 records and included nine studies containing 219 patients in total, individual studies ranging from five to 72 participants. Seven were conducted in Korea and two in Italy, and most enrolled women almost exclusively. The largest was a Korean randomized study of 72 participants treating crow's feet across three sessions, with follow-up to 12 weeks; local treatment-emergent adverse events were reported in 31.9% of participants.
The review's limitations matter more than its conclusions. The authors report that no included study achieved full marks on the CASP critical appraisal checklist, that heterogeneity made a meta-analysis impossible, and that larger samples and longer follow-up are needed. One author discloses an advisory role with a polynucleotide manufacturer.
A 2026 prospective split-face study, also Korean, followed 40 patients across three sessions to week 12, comparing intradermal against subdermal placement rather than against nothing; injection-site embossing occurred only on the intradermal side. The honest summary of this literature is that it is real and growing, and also small, short, and narrow.
Mechanism Two: PDLLA, the JUVELOOK-Type Category
JUVELOOK belongs to a different chemical family. Poly-D,L-lactic acid, abbreviated PDLLA, is a synthetic biodegradable polymer supplied as a freeze-dried powder of microparticles, reconstituted with sterile water before injection. A 2019 correspondence in Clinical and Experimental Dermatology documents how it differs from its older relative, poly-L-lactic acid or PLLA. PLLA particles are solid, irregular, and 40 to 63 micrometers across; PDLLA particles are spherical, carry surface pores, and measure 30 to 70 micrometers. Both resist being engulfed by immune cells yet pass through a needle. Two of that paper's three authors were medical directors of a PDLLA manufacturer, which the paper discloses.
The chemistry drives the behavior. PLLA forms semicrystalline domains; PDLLA's randomly ordered monomers prevent large crystalline regions, leaving it amorphous. A 2024 review in Polymers describes the consequence: PDLLA degrades on a more uniform and predictable schedule, with lactic acid as the terminal breakdown product.
What happens in between is the treatment. A 2024 Delphi consensus of Brazilian dermatologists and plastic surgeons states it plainly: poly-l-lactic-acid fillers stimulate collagen through a subclinical inflammatory response, ultimately increasing type I collagen, with the porous particle acting as a temporary scaffold that new tissue grows around. Cleveland Clinic describes collagen as roughly 30% of the body's total protein and as the material giving skin its structure, strength, and elasticity.
Gradual stimulation is not instant volume
A hyaluronic acid filler produces mechanical volume the moment it is placed. A collagen stimulator produces nothing visible on the day and asks you to wait. The American Academy of Dermatology's consumer page on fillers illustrates the split for the related PLLA material: results from most filler types appear immediately, while PLLA results appear over roughly two to three weeks and are described as lasting one to three years. The Archives of Plastic Surgery overview adds a nuance: PLLA tends to show increasing volume effects over time, while PDLLA is described as producing more consistent effects because the pattern of new tissue growth differs.
Evidence quality here is no stronger than for polynucleotides. The Polymers review grades aesthetic PDLLA studies on the Oxford evidence hierarchy and finds most at level 2b or level 4, with participant counts commonly between 10 and 20. The Brazilian consensus group states outright that clinical trials evaluating PDLLA's aesthetic indications remain limited — which is why a consensus was assembled at all. Expert consensus is legitimate guidance, not trial data.
Mechanism Three: Exosome Preparations, and What an Exosome Actually Is
Cells constantly release small membrane-wrapped packets into the space around them. Under the umbrella term extracellular vesicles, the MISEV2023 consensus document from the International Society for Extracellular Vesicles defines them as lipid bilayer membrane-delimited particles ranging from nanometers to micrometers, released by apparently every cell type studied. "Exosome" refers to a subset formed through a particular internal pathway, roughly 30 to 150 nanometers across. Their cargo can include proteins, lipids, and several kinds of RNA, and the working hypothesis is that this cargo carries signals between cells.
That is genuinely interesting biology. It is also a manufacturing problem. MISEV2023, compiled with input from more than 1,000 researchers, states the difficulty directly: the molecular and structural heterogeneity of extracellular vesicles poses challenges at every stage of study. Its abstract names four obstacles between the science and clinical use — nomenclature, separating vesicles from non-vesicular particles alongside them, characterizing what has been isolated, and demonstrating function.
A 2024 review in Anais Brasileiros de Dermatologia applies that to skin in one sentence: there is no consensus, standardization, or current regulation covering safe extraction, purification, quantification, dose, and posology, which makes multicenter trials difficult to run. A 2025 review of exosomes in aesthetic dermatology agrees, stating that early evidence supports efficacy, that no consensus on outcomes exists, and that no medical guidelines cover appropriate use.
The Regulatory Section U.S. Readers Should Read Twice
None of these three should be assumed to be FDA-approved for cosmetic injection in the United States. The specifics differ by category.
Exosome products. In a public safety notification dated December 6, 2019, the FDA reported multiple serious adverse events in patients in Nebraska treated with unapproved products marketed as containing exosomes. In the same notification the agency stated that there are currently no FDA-approved exosome products, and that as a general matter exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, subject to premarket review and approval. A consumer alert last updated in April 2024 repeats both points.
The agency's advice to patients considering an exosome product in another country is short and practical: learn the regulations that cover products in that country, understand that the FDA does not have oversight of treatments performed abroad and typically has little information about foreign establishments, and be cautious where a country may not require regulatory review of clinical studies.
Underneath the alerts sits a framework rather than a single rule. The FDA's regenerative medicine policy framework consists of four final guidances that together determine when a human cell or tissue product falls outside routine premarket review, with the central tests being minimal manipulation and homologous use under 21 CFR Part 1271. A cultured, processed vesicle preparation injected into skin for cosmetic purposes is a difficult fit for those criteria, which is why such products keep landing in the drug and biologic column.
Polynucleotide and PDLLA products. Different regulatory story, same bottom line. Products of both types marketed in Korea are authorized by Korea's Ministry of Food and Drug Safety, the MFDS, which regulates drugs, medical devices, and cosmetics there. Authorization is national: a product cleared for sale in Seoul has not, by that fact, been evaluated by the FDA for cosmetic use in the United States.
One distinction inside the lactic acid family is easy to get wrong. PLLA appears on the FDA's published list of approved dermal fillers, where the agency notes its effects may last up to two years. PDLLA is the different, amorphous polymer described earlier, and the 2019 composition paper records its approval by the Korean regulator in 2014. If someone tells you a PDLLA product is "the same as Sculptra, so it is FDA-approved," that is two errors at once.
What this means in practice. None of the above says these treatments are illegal, and none of it is an accusation against any clinic offering them where they are lawfully marketed. It says three things. Do not accept "FDA-approved" as a description of any of these three unless the person saying it can point to the specific approval. Get the exact product name and treatment date in writing before you leave, because a physician at home who has never encountered the product will need that record if a delayed reaction appears months later. And if you do experience an adverse event from a regenerative medicine product, the FDA encourages reporting through MedWatch, where such products are treated as drugs on the form.
Matching Mechanism to Concern
There is no single best Korean skin booster, and any source naming one is answering a question the biology does not support. What exists is a match, or a mismatch, between mechanism and finding.
Barrier, hydration, and fine surface texture is where the polynucleotide category is usually positioned, on the strength of a water-binding scaffold plus proposed repair signaling. Its trials measure fine-line and skin quality indices over weeks.
Firmness and collagen-related laxity is what PDLLA is built for, because the endpoint is new type I collagen laid down over months. If skin has lost its snap rather than its moisture, a gradual stimulator addresses the layer in question.
Post-procedure recovery and inflammation-related concerns is where exosome preparations are usually positioned. YONSEI LEEDS CLINIC describes Cell Exosome Therapy for regeneration and inflammation control — the clinic's description of its own option, on an evidence base at the preliminary stage described above.
A fourth answer belongs on the list: none of the three. If what you see is descent of facial tissue or loss of volume, an injectable aimed at skin quality will not fix it.
What YONSEI LEEDS CLINIC States About Its Own Options
The clinic publishes a list of the skin booster formulations it offers, including JUVELOOK, Rejuran Healer, Cell Exosome Therapy, Skin Booster Injection, BNV Biolab SMPF Injection, and Salmon DNA Injection. It describes the underlying technologies as cross-linked hyaluronic acid, PN and PDRN, and cell-derived or plant-derived exosome formulations, with JUVELOOK described as using a patented porous PDLLA structure.
On selection, the clinic describes three steps: a one-to-one consultation covering concerns, history, previous treatments, and goals; a physician skin assessment of elasticity, hydration, texture, and scarring; and customized planning that may use a single formulation or a combination, layered according to the individual skin profile.
On duration, the clinic states that Rejuran Healer effects last approximately six to 12 months and Cell Exosome Therapy approximately two to three months, that JUVELOOK improvement may begin within three to four weeks, and that results develop gradually, are not permanent, and vary between individuals.
Dr. In-Ho Khang is the only physician the clinic profiles, and the clinic states that he personally oversees every treatment. His doctor profile page records an MD from Yonsei University College of Medicine. The clinic describes him as a board-certified specialist without naming the issuing board, so treat that as the clinic's own statement and ask to see the certificate.
Session Courses, and Why the Calendar Decides More Than the Product
The clinic states that JUVELOOK and Rejuran Healer are typically recommended as three-session courses at four-week intervals — roughly a two-month span — and that Salmon DNA Injection and BNV Biolab SMPF Injection may be repeated every one to two weeks, which assumes proximity. Published protocols point the same way: the polynucleotide trials above used three sessions before measuring anything.
A one-week trip cannot contain a three-session course at four-week spacing. The honest options are splitting the course across two visits, choosing a protocol that fits the time you have, or accepting a single session with modest expectations. Ask what happens if you complete only part of the plan.
The clinic states that online consultation is available before travel and that English-speaking support is provided; its inquiry and consultation page is the published route. Seoul runs roughly 13 to 17 hours ahead of the continental United States, so schedule calls accordingly.
Downtime and the Adverse Events Worth Naming Out Loud
The clinic states that temporary side effects may include mild redness, swelling, bruising, or irritation, and that these typically resolve naturally within three to four days. It states most patients return to daily activities within one to two days, and that for about a week after most injection treatments patients are advised to avoid alcohol, smoking, saunas, high-temperature environments, and strenuous exercise.
The literature adds detail that differs by mechanism. For the polynucleotide category, the Korean randomized trial described earlier reported local treatment-emergent adverse events in 31.9% of participants, and the split-face study found embossing only where product was placed intradermally — visible, short-lived, injection-related events.
For particle-based collagen stimulators the profile has a longer tail. A large French observational study of poly-L-lactic acid followed 4,112 treatment courses across 15,665 injection sessions. Overall adverse events were recorded in 18.8% of courses. Non-immediate events occurred in 6.7%: nodules 5.7%, inflammation 0.7%, granuloma 0.3%, and discoloration 0.2%. Onset ranged from 21 days for inflammation to 101 days for granuloma. Two caveats belong with those numbers — the cohort was HIV-positive patients treated for facial lipoatrophy rather than cosmetic patients, and 34% did not attend the review visit.
A 2025 systematic review of foreign body granulomas across six collagen-stimulating products gathered 40 studies and 117 patients. Latency ranged from one week to 15 years, with a mean of about 20 months, and nodules were the most common presentation at 82.9% of cases. The authors state their results cannot establish incidence, because the underlying material is mostly case reports and small series with no standardized definition. A separate 2024 case report describes a granuloma appearing four months after PDLLA injection in one patient.
A useful distinction runs through that literature. A nodule tends to appear within one to two months, is usually linked to placement or technique, and is often solitary. A granuloma reflects a host inflammatory response, appears later, and typically needs steroid treatment. For a traveler, a firm lump appearing three months after you get home is a recognized late pattern for particle-based products — and the reason to keep your record.
Who Should Wait
The clinic's contraindication field for skin boosters is marked as needing clinic confirmation, so there is no published list of who should not have these treatments. Its stated position is that you should inform the clinic about your current skin condition and any recent skin or aesthetic procedures so a medical professional can assess whether treatment is appropriate or should be postponed.
General injectable practice fills the gap. The American Society for Dermatologic Surgery lists active oral herpes or similar infection, uncontrolled diabetes, blood-clotting problems, and lupus or connective tissue disorders among reasons injection may not be recommended. It notes that blood thinners including aspirin and certain herbal supplements are typically stopped about two weeks beforehand with the prescribing physician's approval, and that treatment should be postponed when there is a skin infection. Pregnancy and breastfeeding, a history of keloid scarring, and known allergy to a product's components belong on the same disclosure list. Bring it written down rather than waiting to be asked. The American Academy of Dermatology adds a point worth carrying: injecting a filler is a medical procedure, not a salon service.
What the Clinic Does Not Publish
Naming the gaps is more useful than filling them in. The clinic does not publish a contraindication list for skin boosters, a recommended minimum stay in Korea, case volumes, Dr. Khang's years in practice, booking wait times, travel logistics, payment options, or a named international coordinator. Its registration as a Medical Institution for Attracting Foreign Patients with Korea's Ministry of Health and Welfare permits it to treat foreign patients; it is not a quality accreditation and not a credential recognized in the United States. Ask for the missing items through the clinic's website before booking flights.
The Bottom Line
- There is no single best Korean skin booster among these three. They act through different mechanisms and suit different findings, so the match to your concern matters more than any ranking.
- Rejuran-type polynucleotide products are fragmented fish DNA; supporting trials are small, mostly Korean, and rarely followed beyond 12 weeks.
- JUVELOOK-type PDLLA is a porous synthetic microparticle that stimulates type I collagen over months — a different proposition from a filler that adds volume the same day.
- There are currently no FDA-approved exosome products, and the FDA has issued a public safety notification citing serious adverse events from unapproved products marketed as containing exosomes. Korean MFDS authorization does not equal U.S. authorization.
- Particle-based stimulators carry a documented late tail of nodules and granulomas, so keep the exact product name and treatment date in writing when you fly home.
Frequently Asked Questions
Is there a best Korean skin booster?
There is no defensible answer, because the three categories do different biological jobs. A polynucleotide product is oriented toward hydration, barrier support, and surface texture; a PDLLA product toward collagen stimulation over months; an exosome preparation around regeneration and inflammation, on preliminary evidence. The right comparison is mechanism against your finding, after an in-person skin assessment.
What is the actual difference in Rejuran Healer vs JUVELOOK?
They are different materials with different timelines. Rejuran Healer is in the polynucleotide family, built from fragmented salmon or trout DNA and placed shallowly to influence skin quality. JUVELOOK is in the PDLLA family, a porous microparticle that prompts new type I collagen over months. The clinic states JUVELOOK improvement may begin around three to four weeks, and that Rejuran Healer effects last roughly six to 12 months.
Is exosome therapy vs Rejuran even a fair comparison?
Only loosely. Both are injected and marketed for skin quality, but one is a defined chemical entity with a decade of small published trials behind it, and the other is a biological preparation the field has not yet standardized. MISEV2023 describes heterogeneity as a challenge at every stage of extracellular vesicle work, and a 2024 dermatology review notes no standardization of extraction, purification, or dosing.
Are exosome treatments approved by the FDA?
No. The FDA states there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are generally regulated as drugs and biological products subject to premarket review. It has also published a safety notification describing serious adverse events in patients treated with unapproved exosome products. Lawful marketing in Korea does not create U.S. authorization.
How many sessions will I need, and can I finish in one trip?
Usually not. The clinic states JUVELOOK and Rejuran Healer are typically recommended as three-session courses at four-week intervals, and that some formulations may be repeated every one to two weeks. Discuss splitting the course across visits before booking flights, and ask what a partial course realistically achieves.
What side effects should I watch for after I fly home?
The clinic states mild redness, swelling, bruising, or irritation typically resolve within three to four days. The delayed events worth knowing about belong to particle-based products: published data record nodules and, less commonly, granulomas appearing from about three weeks to many months after injection. A firm lump appearing later warrants medical assessment, and your written product record is what makes that assessment useful.
This article is for general informational purposes and does not constitute individualized medical advice, and it is not a self-diagnosis tool. Surgical candidacy, technique, and expected outcomes can only be determined through a consultation with a qualified plastic surgeon.
More Articles
Continue reading our clinical guides.
Why Korea Body Contouring Prices Stay Low Despite Global Inflation Rise
While global inflation has driven up the cost of surgical procedures in many Western markets, Korean body contouring clinics have maintained stable pricing through efficiency and modern liposuction protocols.
Learn More
Breast Fat Grafting Costs: Korea vs Japan Price Comparison 2026
Autologous breast fat grafting uses a patient's own fat cells to enhance breast volume and shape. Compare 2026 breast fat grafting costs and SVF systems in South Korea vs Japan.
Learn More
Body Lift Efficacy: 90% Satisfaction in Korean Reconstruction Studies
The human body undergoes profound structural modifications following significant weight loss, childbirth, or natural structural aging. Learn how high-precision body lift surgery in Korea achieves 90% patient satisfaction.
Learn More